Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
The principal operating market of Tree Med is Malaysia with revenue predominantly derived from Malaysian customers who contributed approximately 99% of total revenue
whilst the remaining 1% was contributed by overseas customers from, amongst others,Brunei, based on Tree Med's latest audited financial statements for the FYE 31
December 2020. For the FYE 31 December 2020, Tree Med's medical equipment, reagents and consumables were primarily sourced from foreign suppliers from,
amongst others, the United States and Europe (90%) while the remainder was sourced from local suppliers (10%).
i. reagents, supplies, equipment and test kits for blood screening and testing (e.g. for Hepatitis B, Hepatitis C and human immunodeficiency virus (HIV));
ii. clinical chemistry analysers and necessary reagents, chemicals and consumables for clinical chemistry tests;
iii. automated immunoassay analysers and necessary reagents, chemicals and consumables for automated immunoassay tests;
iv. other typical supplies, equipment and consumables for pathology laboratories;
v. COVID-19 test kits including necessary equipment, reagent and consumables such as antigen rapid, total antibody, neutralizing antibody, reverse transcription-polymerase chain reaction (RT-PCR) test kits; and
vi. personal protective equipment and related products including surgical gloves, face masks, thermometers and hand sanitiser.
